Please select the option that best describes you:
What adjuvant therapy would you offer a TNBC patient with residual disease after receiving the neoadjuvant KEYNOTE-522 regimen?
Answer from: Medical Oncologist at Academic Institution
Safety is pembro and cape was provided in phase I trials. Risk and benefit weighing is important when discussing with patients.
Sign In or Register to read more